We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Epistem Announces Evaluation of Genedrive® for Pathogen Detection
News

Epistem Announces Evaluation of Genedrive® for Pathogen Detection

Epistem Announces Evaluation of Genedrive® for Pathogen Detection
News

Epistem Announces Evaluation of Genedrive® for Pathogen Detection

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Epistem Announces Evaluation of Genedrive® for Pathogen Detection"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Epistem Holdings Plc has announced that it has entered into a cooperative agreement with the US Air Force alongside an agreement with Johns Hopkins University (Advanced Physics Laboratory), to undertake the combat evaluation of Epistem's Genedrive® handheld molecular device for pathogen detection.

The agreement will commence immediately and provides $0.6m (GBP 0.4m) over 5 months to develop and evaluate Genedrive® for the identification of three known disease pathogens.

Successful completion of the combat evaluation programme will secure ongoing investment for the development of Genedrive® as a handheld pathogen detection unit for the US Department of Defence.

Preparations for the 2014 launch of the company's first Genedrive® disease test in Tuberculosis continue, with progress to resolve the earlier reported software and firmware issues now nearing completion.

Whilst unit testing is ongoing, preparations are being made for the commencement of final stage clinical trials in support of Indian regulatory approval.

2014 plans to undertake clinical trials with the Foundation for Innovative New Diagnostics (FIND) have also commenced as a forerunner to a potential WHO recommendation in 2015.

Advertisement